Nasus Pharma, Ltd. - NSRX Company Cash Volume

Official company branding of Nasus Pharma Ltd (NSRX)

The cash reserves of Nasus Pharma Ltd (NSRX), as reported by the GURU.Markets system, correlate with the scaling of nasal technologies for allergy treatment. The latest parameter stands at 0.00, although the risk of failed tests and patent disputes could destabilize the capital. Meanwhile, proprietary protection against price wars in the intranasal systems niche supports the current liquidity of the company.

NSRX - nasuspharma.com Company Cash Volume over the range 08/14/2025 - 11/21/2026

Metric breakdowns and analytics for Nasus Pharma Ltd (NSRX)

- stock value and consensus price forecast:
Comprehensive company analysis:Nasus Pharma Ltd NSRX
Signature product of Nasus Pharma, Ltd.

Developing innovative intranasal drug delivery systems requires significant capital expenditures in R&D and certification. Analyzing the cash balance allows for tracking the burn rate of liquid reserves without reporting time lags, which determines the ability of Nasus Pharma Ltd (NSRX) to cover its obligations independently. A stable cash reserve guarantees financial stability, although excess liquidity may signal inefficient capital allocation.